Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RA-BUILD: Baricitinib in cDMARD-IR Rheumatoid Arthritis
NCT01721057Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2012
- Primary completion
- Sep 2014
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial of baricitinib in rheumatoid arthritis (RA) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: American College of Rheumatology 20% Improvement at Week 12. Started Dec 2012; status: completed.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01721057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01721057.